Internal medicine

Prednisolone

Itraconazole

Aspergillus fumigatus

Voriconazole

Immunoglobulin E

Antibody

Dermatology

Asthma

Aspergillosis

Immunology

Combination therapy

Budesonide

Cystic fibrosis

Antifungal

Allergic bronchopulmonary aspergillosis

Medicine

European Respiratory Journal

Glucocorticoids are the most widely used agents in the treatment of allergic bronchopulmonary aspergillosis (ABPA), a disorder characterised by immunologic reactions mounted against Aspergillus fumigatus colonising the airways of patients with asthma and cystic fibrosis [1, 2]. Unfortunately, the use of glucocorticoids is associated with several adverse reactions [3]. A novel treatment strategy in ABPA would be the use of antifungal triazoles as monotherapy. Recently, we have shown that itraconazole was effective as monotherapy in acute-stage ABPA [4]. Whether voriconazole monotherapy is also efficacious in acute-stage ABPA remains unknown. Voriconazole monotherapy is as effective, and safer, than glucocorticoids for the treatment of ABPA <http://ow.ly/jCix30l2Lb9>

A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma